Oxycodone is a semi-synthetic opioid sold under brand names like OxyContin, Roxicodone, and in combination products like Percocet. It is a Schedule II controlled substance, prescribed for moderate to severe pain and frequently encountered in pain management programs, occupational health clinics, and workplace drug testing. Employers and clinics asking how long it stays detectable usually have a more specific question underneath: will a standard opiate panel even catch it, and if it does, what happens when the person has a valid prescription. Both questions matter more than the raw number of hours or days.
Detection windows by specimen type
Detection time depends on the specimen tested, the dose and formulation taken, how often the person uses it, and individual metabolism. The ranges below reflect the pharmacology described in the FDA-approved prescribing information for oxycodone hydrochloride tablets and general toxicology references, not a guarantee for any one person.
| Specimen | Typical detection window | Notes |
|---|---|---|
| Urine | Roughly 1 to 3 days after last use, longer with repeated or high-dose use | Most common specimen for workplace and clinical testing |
| Oral fluid (saliva) | A few hours up to roughly 1 to 2 days | Reflects more recent use than urine |
| Blood | Generally within about 24 hours | Short window, used mostly in clinical or post-accident settings |
| Hair | Up to about 90 days for a standard 1.5 inch head hair segment | Does not capture very recent use, useful for long-term patterns |
Extended-release oxycodone formulations are designed to release the drug over a longer period than immediate-release tablets, which can push the tail end of a detection window slightly further out. The prescribing information for oxycodone hydrochloride tablets, available through the National Library of Medicine's DailyMed label database, describes the drug's absorption and elimination profile in more detail.
Oxycodone versus oxymorphone: the metabolite question
Once oxycodone is absorbed, the liver metabolizes it primarily through two pathways. A large portion converts to noroxycodone, which is largely inactive. A smaller portion converts through the CYP2D6 enzyme into oxymorphone, an active opioid metabolite that is also sold as its own prescription drug (brand name Opana, among others). This is clinically relevant for interpreting results, because a person taking prescribed oxycodone can show oxymorphone in their urine as a normal metabolite, not as evidence they took a separate drug. A physiology reference on oxycodone pharmacology, published on the NIH Bookshelf, walks through this metabolic pathway and the enzymes involved.
How much oxycodone converts to oxymorphone varies by person, because CYP2D6 activity itself varies genetically. Some people metabolize the pathway quickly, others slowly, which is one more reason two people on an identical prescribed dose can produce different immunoassay signal strengths.
Why a standard opiate panel can miss oxycodone
This is the detail that trips up a lot of testing programs. A traditional "OPI" or morphine-based opiate immunoassay is calibrated to detect morphine and codeine, and by extension the illicit opioids that break down into those compounds, such as heroin. Oxycodone and its metabolites have a different chemical structure and do not reliably cross-react with a morphine-calibrated antibody, especially at typical prescribed doses. A person can be taking oxycodone regularly and still test negative on a standard OPI panel.
Because of that gap, testing programs that want to catch oxycodone use need a separate oxycodone-specific immunoassay, usually labeled OXY on a test cup or dip card, run alongside or instead of the standard opiate panel. Pain management clinics, addiction treatment programs, and employers in industries with a documented diversion risk are the most common users of an OXY-specific panel. The distinction between the standard opiate screen and an oxycodone-specific screen is covered in more depth in American Screening Corp's article on whether oxycodone shows up on a drug test. The same panel-selection logic applies to other prescription opioids like hydrocodone, which face the same gap on a standard opiate screen.
Common screening cutoffs
Immunoassay screening tests report a result as positive or negative based on a cutoff concentration, not an exact drug level. For oxycodone-specific immunoassays, 100 ng/mL in urine is a commonly used screening cutoff on commercially available point-of-care cups and dip cards. A specimen that screens positive at that cutoff should still go to confirmation testing, typically gas chromatography-mass spectrometry (GC/MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), before any adverse action is taken. Screening cutoffs and confirmation practices for federally regulated testing programs are described in the Substance Abuse and Mental Health Services Administration's workplace testing guidance, available through SAMHSA's workplace resources. It's worth noting that oxycodone is not one of the five drug classes included in the federal Mandatory Guidelines used for DOT-regulated testing, so DOT panels alone will not flag it; programs that need oxycodone coverage add it as a non-regulated expanded panel item.
Prescription verification through the MRO
A positive result on an oxycodone panel is not the end of the process in a properly run program. Non-negative results go through review by a Medical Review Officer (MRO), a licensed physician trained to evaluate lab results and determine whether a legitimate medical explanation accounts for the finding. If the person has a valid, current prescription for oxycodone or a medication that metabolizes into it, and they are able to produce that information when the MRO contacts them, the MRO can verify the result as negative for reporting purposes. This is why anyone taking a prescribed opioid should be prepared to disclose it to the MRO when asked, rather than to the collector or their employer directly. The general framework for verification, direct MRO contact, and confidential handling of prescription information sits within 49 CFR Part 40, the Department of Transportation's drug testing regulation, viewable through the eCFR version of 49 CFR Part 40. Non-DOT programs commonly model their MRO review process on the same structure even though they are not legally required to.
Employers building a testing program that includes an OXY panel should have a clear, written policy on how prescription disclosure and MRO verification work before the first sample is collected, not after a result comes back non-negative.
Factors that affect an individual detection window
- Dose and formulation. Higher doses and extended-release formulations tend to stay detectable longer than a single low-dose immediate-release tablet.
- Frequency and duration of use. Repeated daily use over days or weeks generally extends the detection window compared to a single dose.
- Individual metabolism. CYP2D6 enzyme activity varies by person and affects how quickly oxycodone converts to oxymorphone and clears the body.
- Liver and kidney function. Since the liver metabolizes oxycodone and the kidneys excrete the metabolites, impaired function in either organ can extend detection time.
- Hydration and urine concentration. More dilute urine generally shows a lower drug concentration, which can matter near a cutoff threshold.
- Specimen type. As the table above shows, blood and oral fluid reflect recent use, urine covers a somewhat longer window, and hair reflects a much longer history.
None of these factors let a testing program or an individual predict an exact hour or day when a result will turn negative. They explain why two people with what looks like a similar history can get different results, and why programs rely on lab confirmation rather than a single screening number.
Choosing the right panel
For employers and clinics deciding what to stock, the practical question is whether a standard opiate panel is sufficient for the population being tested or whether an oxycodone-specific panel needs to be added. Pain management programs monitoring compliance with a prescribed regimen typically need the OXY-specific panel by design, since the entire point is confirming the prescribed drug is present and nothing else is. General workplace programs should weigh the risk of prescription opioid misuse in their workforce against the cost of an expanded panel. A full range of opiate and oxycodone-specific test cups and cards is available through American Screening Corp's drug testing collection. Cutoff levels for oxycodone alongside other common panel drugs are laid out in more detail in the SAMHSA and DOT drug testing cutoff levels reference table.
Frequently asked questions
Will a standard 5 panel drug test catch oxycodone?
Usually not reliably. A standard opiate immunoassay is calibrated to morphine and codeine and does not consistently cross-react with oxycodone at typical prescribed doses. A separate oxycodone-specific (OXY) immunoassay is needed to reliably detect it.
Does a positive oxycodone result mean the person took something illegal?
Not necessarily. A positive screen only shows the drug or its metabolite was present above the cutoff. A Medical Review Officer reviews the result and can verify it as negative for reporting purposes if the person has a valid prescription and discloses it during MRO contact.
Why did I test positive for oxymorphone when I only take oxycodone?
Oxymorphone is a normal metabolite of oxycodone. The liver converts a portion of any oxycodone dose into oxymorphone through the CYP2D6 enzyme, so its presence alongside oxycodone is expected and does not indicate use of a separate drug.
How long does oxycodone stay detectable in urine specifically?
Urine is generally the longest common workplace testing window, typically in the range of one to three days after last use, though repeated use, higher doses, and extended-release formulations can extend that range.
What cutoff do most oxycodone drug tests use?
Many commercially available oxycodone-specific immunoassay cups and cards use a 100 ng/mL screening cutoff in urine. Any presumptive positive should be sent for laboratory confirmation before being treated as a final result.
Related reading
This article is general information, not medical or legal advice. Detection windows vary by individual and are not a substitute for laboratory confirmation or professional medical guidance. Anyone taking a prescribed opioid should disclose it to the Medical Review Officer during the verification process rather than relying on a screening result alone.
